Compugen Ltd (CGEN) stock
CGENNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
$2.10−0.02 (-0.94%)
Close on Nov 13, 2026Market cap $198.56MP/E 5.5Yield –
Compugen r&d expenses
Research and development expenses are spending on new products and technology.
For fiscal 2025 it was $22.76M, down 8.3% from the year before. Over ten years it grew 0.7% a year on average. The highest annual figure on record is $34.47M in fiscal 2023.
Annual r&d expenses
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $22.76M | -8.3% |
| FY2024 | Dec 31, 2024 | $24.81M | -28.0% |
| FY2023 | Dec 31, 2023 | $34.47M | +12.5% |
| FY2022 | Dec 31, 2022 | $30.65M | +6.8% |
| FY2021 | Dec 31, 2021 | $28.69M | +26.1% |
| FY2020 | Dec 31, 2020 | $22.76M | +14.9% |
| FY2019 | Dec 31, 2019 | $19.82M | -34.6% |
| FY2018 | Dec 31, 2018 | $30.32M | +6.1% |
| FY2017 | Dec 31, 2017 | $28.58M | +16.4% |
| FY2016 | Dec 31, 2016 | $24.55M | +15.6% |
| FY2015 | Dec 31, 2015 | $21.25M | +40.9% |
| FY2014 | Dec 31, 2014 | $15.07M | +22.8% |
| FY2013 | Dec 31, 2013 | $12.28M | +30.0% |
| FY2012 | Dec 31, 2012 | $9.44M | +39.3% |
| FY2011 | Dec 31, 2011 | $6.78M | +29.7% |
| FY2010 | Dec 31, 2010 | $5.23M | +3.5% |
| FY2009 | Dec 31, 2009 | $5.05M | – |
See a number that looks wrong?